Sang M. Park

Suwon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Diabetes reprograms brain and systemic immune landscapes to impair repair after injury.

Diabetes reprograms brain and systemic immune landscapes to impair repair after injury.

Journal: Molecular brain

Published: January 12, 2026

Uncovering the role of c-Fos in the bidirectional relationship between depression/anxiety behaviors and α-synuclein propagation in Parkinson's disease.

Uncovering the role of c-Fos in the bidirectional relationship between depression/anxiety behaviors and α-synuclein propagation in Parkinson's disease.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: August 17, 2025

A human striatal-midbrain assembloid model of alpha-synuclein propagation.

A human striatal-midbrain assembloid model of alpha-synuclein propagation.

Journal: Brain : a journal of neurology

Published: March 27, 2025

Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson's Disease.

Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson's Disease.

Journal: Cells

Published: October 15, 2024

GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson's disease animal models.

GPR40 agonist ameliorates neurodegeneration and motor impairment by regulating NLRP3 inflammasome in Parkinson's disease animal models.

Journal: Pharmacological research

Published: March 29, 2024

The LRRK2-G2019S mutation attenuates repair of brain injury partially by reducing the release of osteopontin-containing monocytic exosome-like vesicles.

The LRRK2-G2019S mutation attenuates repair of brain injury partially by reducing the release of osteopontin-containing monocytic exosome-like vesicles.

Journal: Neurobiology of disease

Published: February 19, 2024

Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation: Implications in Parkinson's disease.

Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation: Implications in Parkinson's disease.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 21, 2023

Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson's disease.

Integration of National Health Insurance claims data and animal models reveals fexofenadine as a promising repurposed drug for Parkinson's disease.

Journal: Journal of neuroinflammation

Published: November 13, 2023

Gut-brain axis: gut dysbiosis and psychiatric disorders in Alzheimer's and Parkinson's disease.

Gut-brain axis: gut dysbiosis and psychiatric disorders in Alzheimer's and Parkinson's disease.

Journal: Frontiers in neuroscience

Published: July 29, 2023

Monitoring α-synuclein Aggregation Induced by Preformed α-synuclein Fibrils in an In Vitro Model System.

Monitoring α-synuclein Aggregation Induced by Preformed α-synuclein Fibrils in an In Vitro Model System.

Journal: Experimental neurobiology

Published: February 08, 2023

Critical roles of parkin and PINK1 in coxsackievirus B3-induced viral myocarditis.

Critical roles of parkin and PINK1 in coxsackievirus B3-induced viral myocarditis.

Journal: Microbes and infection

Published: October 02, 2022

Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease.

Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: July 20, 2022

Showing 1-12 of 50

Last Updated: 09/26/2026